GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oruka Therapeutics ORKA · USD

Health Care · US listing · 🇺🇸 United States

Compare

104.56

+1.65%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$105.4m

FY2016FY2025

Free cash flow

−$88.4m

FY2016FY2025

Shareholders' equity

$471.9m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross profit−$83,000−$27,000−$111,000−$114,000−$91,000−$93,000−$89,000−$22,000−$27,000−$24,000
Research and development$100.6m$75.1m$1.0m$4.5m$13.8m$5.0m$1.8m$4.2m$14.1m$12.3m
Operating income−$122.1m−$88.1m−$7.3m−$9.8m−$19.3m−$9.8m−$5.8m−$8.1m−$18.7m−$16.6m
Net income−$105.4m−$83.7m−$5.3m−$9.9m−$19.3m−$9.7m−$5.5m−$7.9m−$18.5m−$16.4m
Diluted earnings per share-1.94-4.99-0.37-8.27-16.09-12.24-41.28-122.99-339.27-391.73

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$488.6m$396.0m$37.9m$43.1m$54.9m$50.4m$8.5m$6.8m$12.4m$24.6m
Cash and short-term investments$337.0m$375.6m$37.4m$42.4m$53.4m$49.1m$8.4m$6.6m$11.8m$21.2m
Total liabilities$16.7m$13.8m$841,000$1.4m$3.9m$3.9m$926,000$793,000$2.1m$2.4m
Debt$619,000—————————
Shareholders' equity$471.9m$382.2m$37.0m$41.7m$51.0m$46.5m$7.6m$6.0m$10.3m$22.2m
Shares outstanding54m17m14m1m1m1m0m0m0m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$88.2m−$57.8m−$5.0m−$10.9m−$18.8m−$7.7m−$4.8m−$8.2m−$17.5m−$15.0m
Capital spending−$209,000−$189,000—−$2,000−$43,000−$19,000−$4,000−$3,999−$3,000−$12,000
Free cash flow−$88.4m−$58.0m−$5.0m−$10.9m−$18.8m−$7.7m−$4.8m−$8.2m−$17.5m−$15.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit−$43,000−$43,000−$28,000—−$19,000−$16,000−$16,000$20,000
Operating income−$50.1m−$36.4m−$34.4m−$34.1m−$28.4m−$25.1m−$38.3m−$29.4m
Net income−$41.2m−$31.8m−$29.6m−$30.3m−$24.6m−$21.0m−$33.4m−$28.6m
Diluted earnings per share-0.66-0.51-0.54-0.56-0.45-0.39-1.99-1.70
Cash from operations−$33.0m−$23.0m−$22.0m−$21.0m−$23.0m−$20.0m−$18.0m−$34.0m
Total assets$1.14bn$504.5m$488.6m$509.3m$357.4m$377.1m$396.0m$414.1m
Cash and short-term investments$873.6m$388.8m$337.0m$349.2m$328.4m$349.1m$375.6m$410.9m
Debt$669,000$680,000$619,000$419,000$660,000$283,000$213,000$146,000
Shareholders' equity$1.11bn$486.7m$471.9m$486.8m$343.6m$364.7m$382.2m$342.4m

Financial ratios

Data as of 2 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2012FY2011FY2010FY2007FY2006FY2005
Gross margin——————————95.0%18.2%-10501.5%
Operating margin——————————-26.0%-3399.9%-12905.3%
Net margin——————————-26.2%-3415.0%-13139.6%
Return on equity-22.3%-21.9%-14.4%-23.8%-37.9%-20.9%———————
Return on assets-21.6%-21.1%-14.1%-23.0%-35.2%-19.3%———————
Free cash flow yield-1.7%-3.5%—-9.4%-16.1%-10.0%-37.3%——————
Revenue growth——————————1105.3%613.4%—
Earnings growth25.9%1468.2%-46.2%-48.6%98.4%77.6%———————
Current ratio22.37x28.89x59.01x37.72x15.56x14.28x———————
Debt to equity0.00x0.00x0.00x0.00x0.00x0.00x———————
Equity ratio96.6%96.5%97.8%96.7%92.9%92.3%———————
Interest coverage—-56.03x———-1082.00x-806.00x-1439.00x-1071.80x-1051.50x———
R&D as a share of sales——————————91.0%2298.6%—
Buybacks as a share of market value-224.1%-16.5%-1100.5%0.0%-50.9%-499.2%———————

Growth per year

Compound annual rate

3 years5 years10 years
Operating income131.5%65.7%26.7%
Net income119.8%61.0%24.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-15.6-3.9-55.1-3.4-1.6-3.9-1.7-0.6-0.6-1.0

Market value over time

30 Nov 2016 to 30 Oct 2026, in USD

$507.6m$6.09bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return32%0%-26%3%-45%-26%-6%-62%-46%-44%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 29 Aug 2024.

FY2024
Paid in the year19.356
  • 12-to-1 reverse split · 3 Sept 2024
  • 18-to-1 reverse split · 4 Apr 2019
  • 7-to-1 reverse split · 4 Sept 2015
  • 6-to-1 reverse split · 5 Mar 2013
  • 20-to-1 reverse split · 28 Jan 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.